These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 22565037)

  • 1. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
    Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
    Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
    Breast Cancer Res Treat; 2011 Apr; 126(2):355-64. PubMed ID: 20458531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castillo B; Cufí S; Del Barco S; Lopez-Bonet E; Brunet J; Menendez JA
    Biochem Biophys Res Commun; 2010 Jun; 397(1):27-33. PubMed ID: 20470755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
    Duru N; Fan M; Candas D; Menaa C; Liu HC; Nantajit D; Wen Y; Xiao K; Eldridge A; Chromy BA; Li S; Spitz DR; Lam KS; Wicha MS; Li JJ
    Clin Cancer Res; 2012 Dec; 18(24):6634-47. PubMed ID: 23091114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
    Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
    Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
    Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
    Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.
    Cirenajwis H; Smiljanic S; Honeth G; Hegardt C; Marton LJ; Oredsson SM
    Anticancer Drugs; 2010 Nov; 21(10):897-906. PubMed ID: 20838207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
    Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
    Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.
    Park M; Jung E; Park JM; Park S; Ko D; Seo J; Kim S; Nam KD; Kang YK; Farrand L; Hoang VH; Nguyen CT; La MT; Nam G; Park HJ; Ann J; Lee J; Kim YJ; Kim JY; Seo JH
    Theranostics; 2024; 14(6):2442-2463. PubMed ID: 38646654
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).
    Diessner J; Bruttel V; Stein RG; Horn E; Häusler SF; Dietl J; Hönig A; Wischhusen J
    Cell Death Dis; 2014 Mar; 5(3):e1149. PubMed ID: 24675467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties.
    Sun H; Jia J; Wang X; Ma B; Di L; Song G; Ren J
    Clin Transl Oncol; 2013 Jan; 15(1):46-54. PubMed ID: 22855175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
    Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
    Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
    Gardaneh M; Shojaei S; Kaviani A; Behnam B
    Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
    Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
    Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.
    Zhu Y; Zhang X; Liu Y; Zhang S; Liu J; Ma Y; Zhang J
    Tumour Biol; 2012 Oct; 33(5):1349-62. PubMed ID: 22492237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
    Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
    J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.